Kitasato Daiichi Sankyo Vaccine submits NDA in Japan for influenza vaccine

Kitasato Daiichi Sankyo Vaccine Co., Ltd., the domestic subsidiary of Daiichi Sankyo Company, Ltd., announced its submission on Wednesday of a new drug application for its cell culture-based pandemic influenza vaccine.

Kitasato Daiichi submitted the application to Japan's Ministry of Health, Labor and Welfare. In August 2011, Kitasato Daiichi received a grant from the ministry for a cell culture vaccine production facility and for the development of the vaccine. Since that time, Kitasato Daiichi worked diligently to increase production capacity by the end of March 2014.

Daiichi Sankyo and Kitasato Daiichi said they would work to contribute to Japanese public health through the rapid production of a stable supply of vaccine that could be used in the event of a pandemic.

According to the company's website, Daiichi Sankyo is a global pharmaceutical company that engages in research and development, manufacturing and sales and marketing of generic and innovative drugs, vaccines and over-the-counter medicines. The company provides products and services in more than 50 countries worldwide and uses more than 100 years of scientific expertise to draw upon its legacy of innovation and its robust pipeline of promising new medicines.

Daiichi Sankyo's research and development pipeline includes multiple drugs in Phase I, Phase II and Phase III trials including treatments for cancer, rheumatoid arthritis and diabetes.